Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ESRRB | O95718 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531381 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14GAACA12CHRNB2 | |
| SCHEMBL29531261 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14GAACA12CHRNB2 | |
| SCHEMBL7781829 | 0.87 | ALDH1A1 (0.34) | SMN1; SMN2GAACA12ALDH1A1HSD17B10 | |
| SCHEMBL31462139 | 0.81 | CHRNB2 (0.37) | CHRNB2CHRNA4ALDH1A1HSD17B10TSHR | |
| SCHEMBL11668486 | 0.79 | ALDH1A1 (0.40) | SMN1; SMN2GAACA12ALDH1A1HSD17B10 | |
| SCHEMBL10736806 | 0.79 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12CHRNB2CHRNA4 | |
| SCHEMBL8747892 | 0.77 | L3MBTL1 (0.41) | SMN1; SMN2CA14GAACA12ALDH1A1 | |
| SCHEMBL13307459 | 0.77 | CHRNB2 (0.39) | SMN1; SMN2CA14CHRNB2CHRNA4CA1 | |
| SCHEMBL10947530 | 0.77 | TSHR (0.43) | SMN1; SMN2CA14GAACA12ALDH1A1 | |
| SCHEMBL16939082 | 0.76 | SMN1; SMN2 (0.37) | SMN1; SMN2CA14GAACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858875-B2 | Propenylamines and methods of making and using same | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3084152-B1 | FLUORINATED OLEFINS AS WORKING FLUIDS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-08-04 | — | — | US | disclosed |
| WO-2020118238-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3169745-B1 | HYDROFLUOROETHER OLEFINS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10557069-B2 | Fluorinated olefins as working fluids and methods of using same | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-10385249-B2 | Hydrofluoroether olefins and methods of using same | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-6506939-B1 | Producing N-substituted acrylamides and tertiary amines | CIBA SPECIALTY CHEMICALS WATER TREATMENTS LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| CN-1345302-A | Method for producing acrylic acid monomer | CIBA SPEC CHEM WATER TREAT LTD (GB) | 2002-04-17 | — | — | CN | disclosed |
| US-5476934-A | Oxidation a nitrogen-containing perfluoroacyl halide | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY, MINISTRY OF INTERNATIONAL TRADE & INDUSTRY (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5380844-A | Nitrogen-containing perfluoroalkanoyl peroxide and method for production thereof | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY, MINISTRY OF INTERNATIONAL TRADE & INDUSTRY (JP) | 1995-01-10 | — | — | US | disclosed |
| US-5347002-A | Nitrogen-containing perfluoroalkanoyl peroxide and method for production thereof | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1994-09-13 | — | — | US | disclosed |
| US-5256825-A | Promoter for fluoropolymer, heat exchanging | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1993-10-26 | — | — | US | disclosed |
| US-5208339-A | Nitrogen-containing perfluoroalkanoyl peroxide and method for production thereof | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1993-05-04 | — | — | US | disclosed |
| US-4985556-A | INTERMEDIATES | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1991-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SLC10A2, SLC10A1, BCAT2 | SMN1; SMN2 2918/4885CA14 1563/4885GAA 899/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | SMN1; SMN2 2802/4885CA14 2077/4885GAA 1423/4885 |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | SMN1; SMN2 2802/4885CA14 2077/4885GAA 1423/4885 |
| US-11858875-B2 | Propenylamines and methods of making and using same | RFT1, AFF1, AFF2 | SMN1; SMN2 1333/4885CA14 4031/4885GAA 4845/4885 |
| US-10385249-B2 | Hydrofluoroether olefins and methods of using same | SLC46A1, CYP4F2, FANCF | SMN1; SMN2 2307/4885CA14 183/4885GAA 2118/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | SMN1; SMN2 4351/4885CA14 4227/4885GAA 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.